Related Experiment Videos
Treatment of Liver Cancer by C/EBPA saRNA
Xiaoyang Zhao1, Jon Voutila2, Stephanos Ghobrial1
1Department of Surgery, Hammersmith Hospital, Imperial College London, London, UK.
Abstract:
The prognosis for hepatocellular carcinoma (HCC) remains poor and has not improved in over two decades. Most patients with advanced HCC who are not eligible for surgery have limited treatment options due to poor liver function or large, unresectable tumors. Although sorafenib is the standard-of-care treatment for these patients, only a small number respond. For the remaining, the outlook remains bleak. A better approach to target "undruggable" molecular pathways that reverse HCC is therefore urgently needed. Small activating RNAs (saRNAs) may provide a novel strategy to activate expression of genes that become dysregulated in chronic disease. The transcription factor CCAAT/enhancer-binding protein alpha (C/EBPα), a critical regulator of hepatocyte function, is suppressed in many advanced liver diseases. By using an saRNA to activate C/EBPα, we can exploit the cell's own transcription machinery to enhance gene expression without relying on exogenous vectors that have been the backbone of gene therapy. saRNAs do not integrate into the host genome and can be modified to avoid immune stimulation. In preclinical models of liver disease, treatment with C/EBPα saRNA has shown reduction in tumor volume and improvement in serum markers of essential liver function such as albumin, bilirubin, aspartate aminotransferase (AST), and alanine transaminase (ALT). This saRNA that activates C/EBPα for advanced HCC is the first saRNA therapy to have entered a human clinical trial. The hope is that this new tool will help break the dismal 20-year trend and provide a more positive prognosis for patients with severe liver disease.
Insights
A novel small activating RNA (saRNA) therapy targeting CCAAT/enhancer-binding protein alpha (C/EBPα) shows promise for advanced hepatocellular carcinoma (HCC). This approach activates a key gene, potentially improving outcomes for patients with limited treatment options.
Area of Science:
- Hepatocellular Carcinoma (HCC) Research
- Gene Therapy and RNA Therapeutics
- Molecular Oncology
Background:
- Hepatocellular carcinoma (HCC) prognosis is poor, with limited treatment options for advanced stages.
- Current standard-of-care, sorafenib, has a low response rate in advanced HCC.
- There is an urgent need for novel therapeutic strategies targeting "undruggable" molecular pathways in HCC.
Purpose of the Study:
- To investigate the potential of small activating RNAs (saRNAs) to reverse HCC progression.
- To evaluate the efficacy of an saRNA targeting CCAAT/enhancer-binding protein alpha (C/EBPα) in HCC.
- To assess the safety and therapeutic potential of C/EBPα saRNA as a novel HCC treatment.
Main Methods:
- Utilized saRNA technology to activate the suppressed transcription factor C/EBPα, a regulator of hepatocyte function.
- Exploited the cell's endogenous transcription machinery for gene expression enhancement.
- Conducted preclinical studies in liver disease models and initiated a human clinical trial for advanced HCC.
Main Results:
- Preclinical models demonstrated a reduction in tumor volume with C/EBPα saRNA treatment.
- Improved serum markers of liver function, including albumin, bilirubin, AST, and ALT, were observed.
- The C/EBPα saRNA is the first of its kind to enter human clinical trials for advanced HCC.
Conclusions:
- saRNA-mediated activation of C/EBPα represents a novel therapeutic strategy for advanced HCC.
- This approach offers a potential alternative to conventional treatments with limited efficacy.
- The C/EBPα saRNA therapy holds promise for improving the dismal prognosis of severe liver disease.